Affinity chromatography reveals direct binding of the GATA4–NKX2-5 interaction inhibitor (3i-1000) with GATA4
Abstract Heart failure is a serious medical condition with a poor prognosis. Current treatments can only help manage the symptoms and slow the progression of heart failure. However, there is currently no cure to prevent and reverse cardiac remodeling. Transcription factors are in a central role in v...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-59418-4 |
| _version_ | 1797199525024104448 |
|---|---|
| author | Mikael Jumppanen Sini M. Kinnunen Matej Zore Mika J. Välimäki Virpi Talman Gustav Boije af Gennäs Heikki J. Ruskoaho Jari Yli-Kauhaluoma |
| author_facet | Mikael Jumppanen Sini M. Kinnunen Matej Zore Mika J. Välimäki Virpi Talman Gustav Boije af Gennäs Heikki J. Ruskoaho Jari Yli-Kauhaluoma |
| author_sort | Mikael Jumppanen |
| collection | DOAJ |
| description | Abstract Heart failure is a serious medical condition with a poor prognosis. Current treatments can only help manage the symptoms and slow the progression of heart failure. However, there is currently no cure to prevent and reverse cardiac remodeling. Transcription factors are in a central role in various cellular processes, and in the heart, GATA4 and NKX2-5 transcription factors mediate hypertrophic responses and remodeling. We have identified compounds that modulate the synergistic interaction of GATA4 and NKX2-5 and shown that the most promising compound (1, 3i-1000) is cardioprotective in vitro and in vivo. However, direct evidence of its binding site and mechanism of action has not been available. Due to the disordered nature of transcription factors, classical target engagement approaches cannot be utilized. Here, we synthesized a small-molecule ligand-binding pulldown probe of compound 1 to utilize affinity chromatography alongside CETSA, AlphaScreen, and molecular modeling to study ligand binding. These results provide the first evidence of direct physical binding of compound 1 selectively to GATA4. While developing drugs that target transcription factors presents challenges, advances in technologies and knowledge of intrinsically disordered proteins enable the identification of small molecules that can selectively target transcription factors. |
| first_indexed | 2024-04-24T07:17:08Z |
| format | Article |
| id | doaj.art-2029b729860d4650ad7fb8a5f2680938 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-24T07:17:08Z |
| publishDate | 2024-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-2029b729860d4650ad7fb8a5f26809382024-04-21T11:14:11ZengNature PortfolioScientific Reports2045-23222024-04-0114111310.1038/s41598-024-59418-4Affinity chromatography reveals direct binding of the GATA4–NKX2-5 interaction inhibitor (3i-1000) with GATA4Mikael Jumppanen0Sini M. Kinnunen1Matej Zore2Mika J. Välimäki3Virpi Talman4Gustav Boije af Gennäs5Heikki J. Ruskoaho6Jari Yli-Kauhaluoma7Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of HelsinkiDrug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of HelsinkiDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of HelsinkiDrug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of HelsinkiDrug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of HelsinkiDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of HelsinkiDrug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of HelsinkiDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of HelsinkiAbstract Heart failure is a serious medical condition with a poor prognosis. Current treatments can only help manage the symptoms and slow the progression of heart failure. However, there is currently no cure to prevent and reverse cardiac remodeling. Transcription factors are in a central role in various cellular processes, and in the heart, GATA4 and NKX2-5 transcription factors mediate hypertrophic responses and remodeling. We have identified compounds that modulate the synergistic interaction of GATA4 and NKX2-5 and shown that the most promising compound (1, 3i-1000) is cardioprotective in vitro and in vivo. However, direct evidence of its binding site and mechanism of action has not been available. Due to the disordered nature of transcription factors, classical target engagement approaches cannot be utilized. Here, we synthesized a small-molecule ligand-binding pulldown probe of compound 1 to utilize affinity chromatography alongside CETSA, AlphaScreen, and molecular modeling to study ligand binding. These results provide the first evidence of direct physical binding of compound 1 selectively to GATA4. While developing drugs that target transcription factors presents challenges, advances in technologies and knowledge of intrinsically disordered proteins enable the identification of small molecules that can selectively target transcription factors.https://doi.org/10.1038/s41598-024-59418-4 |
| spellingShingle | Mikael Jumppanen Sini M. Kinnunen Matej Zore Mika J. Välimäki Virpi Talman Gustav Boije af Gennäs Heikki J. Ruskoaho Jari Yli-Kauhaluoma Affinity chromatography reveals direct binding of the GATA4–NKX2-5 interaction inhibitor (3i-1000) with GATA4 Scientific Reports |
| title | Affinity chromatography reveals direct binding of the GATA4–NKX2-5 interaction inhibitor (3i-1000) with GATA4 |
| title_full | Affinity chromatography reveals direct binding of the GATA4–NKX2-5 interaction inhibitor (3i-1000) with GATA4 |
| title_fullStr | Affinity chromatography reveals direct binding of the GATA4–NKX2-5 interaction inhibitor (3i-1000) with GATA4 |
| title_full_unstemmed | Affinity chromatography reveals direct binding of the GATA4–NKX2-5 interaction inhibitor (3i-1000) with GATA4 |
| title_short | Affinity chromatography reveals direct binding of the GATA4–NKX2-5 interaction inhibitor (3i-1000) with GATA4 |
| title_sort | affinity chromatography reveals direct binding of the gata4 nkx2 5 interaction inhibitor 3i 1000 with gata4 |
| url | https://doi.org/10.1038/s41598-024-59418-4 |
| work_keys_str_mv | AT mikaeljumppanen affinitychromatographyrevealsdirectbindingofthegata4nkx25interactioninhibitor3i1000withgata4 AT sinimkinnunen affinitychromatographyrevealsdirectbindingofthegata4nkx25interactioninhibitor3i1000withgata4 AT matejzore affinitychromatographyrevealsdirectbindingofthegata4nkx25interactioninhibitor3i1000withgata4 AT mikajvalimaki affinitychromatographyrevealsdirectbindingofthegata4nkx25interactioninhibitor3i1000withgata4 AT virpitalman affinitychromatographyrevealsdirectbindingofthegata4nkx25interactioninhibitor3i1000withgata4 AT gustavboijeafgennas affinitychromatographyrevealsdirectbindingofthegata4nkx25interactioninhibitor3i1000withgata4 AT heikkijruskoaho affinitychromatographyrevealsdirectbindingofthegata4nkx25interactioninhibitor3i1000withgata4 AT jariylikauhaluoma affinitychromatographyrevealsdirectbindingofthegata4nkx25interactioninhibitor3i1000withgata4 |